01—Abstract
Summary
Summary of the 8-K filed August 6, 2026. Cited figures are marked; the original filing is the authoritative source.
Zoetis (ZTS) announced that James "Jay" Saccaro will become Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026.
The role is newly created and combines the global finance function (capital allocation, financial strategy, reporting and controls, investor engagement) with oversight of Global Manufacturing and Supply. Saccaro will be the principal financial and principal accounting officer. He comes from GE HealthCare, where he has been CFO since June 2023, and previously spent roughly eight years as CFO of Baxter International.
The 8-K also reports a planned CFO transition: Wetteny Joseph, the current EVP and CFO, will step down from the executive role after August 16, 2026 and remain a non-executive officer until the earlier of February 28, 2027 or a mutually agreed date. The company states his departure was not due to any disagreement on operations, policies, practices, accounting, or internal controls. Saccaro's compensation package includes a $1,000,000a base salary, a 100% of salary target bonus (2026 paid at target and pro-rated), and a $5,000,000 annual long-term incentive target (50% PSUs, 25% RSUs, 25% stock options).
He also receives a one-time make-whole RSU award with a $6,250,000b grant-date value vesting in thirds over three years, plus a $1,250,000 one-time cash award subject to repayment if he is terminated under certain circumstances within his first year. Joseph will keep his base salary, benefits and equity vesting through his termination date, may earn a 2026 annual incentive at target subject to company performance funding, and will receive Executive Severance Plan benefits on departure. His outstanding equity will be treated as a Restructuring Event.
For investors, the key points are continuity of finance leadership through a planned handover and the expanded mandate, which places manufacturing and supply under the CFO and signals a focus on operational execution alongside capital allocation. The filing does not discuss financial results or guidance changes. The make-whole awards and the planned CEO-level reporting of Joseph as a special advisor on financial matters through early 2027 suggest a deliberately managed transition rather than an abrupt departure.
02—Key points
Key Highlights
- James "Jay" Saccaro, formerly CFO of GE HealthCare (since June 2023) and CFO of Baxter International (2015–2023), will become EVP, CFO and COO effective August 17, 2026.
- The newly created role combines global finance leadership with oversight of Global Manufacturing and Supply, signaling a push for operational execution alongside capital allocation.
- Saccaro's pay package: $1.0M base salary, 100% target bonus, $5.0M annual LTI target, plus a $6.25M one-time RSU make-whole award (three-year ratable vesting) and a $1.25M cash make-whole award subject to clawback.
- Wetteny Joseph, the current EVP and CFO, transitions to a non-executive advisory role after August 16, 2026, remaining through the earlier of February 28, 2027 or a mutually agreed date.
- The company states Joseph's departure was not due to any disagreement with Zoetis on operations, policies, practices, accounting, financial disclosure, or internal controls.
- Joseph keeps his salary, benefits and equity vesting through his termination date, may earn a 2026 bonus at target subject to performance funding, and receives Executive Severance Plan benefits, with equity treated as a Restructuring Event.
- No financial results or guidance were disclosed in this filing; the 8-K is limited to executive changes and compensation.
03—Questions
Frequently Asked Questions
Who is replacing Wetteny Joseph as CFO, and when does the change take effect?
James (Jay) Saccaro, currently VP and CFO of GE HealthCare, becomes EVP, CFO and COO effective August 17, 2026. Joseph transitions to a non-executive advisory role after August 16, 2026, and remains through the earlier of February 28, 2027 or a mutually agreed date.
Was Joseph's departure related to any accounting or internal control issue?
No. The 8-K states that Joseph's departure was not due to any disagreement with the company on operations, policies, practices, accounting principles, financial statement disclosure, or internal controls.
What does Saccaro's compensation look like, and are there any unusual items?
His base salary is $1.0M, with a 100% target bonus and a $5.0M annual LTI target. The make-whole package is notable: a $6.25M RSU grant vesting in thirds over three years, and a $1.25M cash award that must be repaid if he is terminated for certain reasons within his first year.
Why is the new role broader than a typical CFO position?
The role is newly created and adds oversight of Global Manufacturing and Supply to the global finance function. The company says this is intended to drive operational execution, supply chain and distribution performance, and operational excellence alongside capital allocation and financial strategy.
Does this filing change Zoetis's financial outlook?
The filing does not include financial results, guidance, or outlook. It only covers the executive appointment, the CFO transition, and related compensation arrangements.
04—Continue